EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Treat‐To‐Target: Emergence of Second‐Generation CD 40 L Inhibitors for Treatment of SLE —Identifying Beneficial Patient Candidates for CD 40 L Inhibitors in a Cross‐Sectional SLE Cohort

Kathrine Pedersen iD, Annette Gudmann Hansen, Yaseelan Palarasah, Anne Troldborg, Steffen Thiel

Scandinavian Journal of Immunology · 2025

DOI: 10.1111/sji.70050 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Scandinavian Journal of Immunology, 2025. Verfasst von Kathrine Pedersen und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, CD40 Ligand. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Danmarks Grundforskningsfond.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterised by heterogeneous clinical manifestations and varying degrees of organ involvement. The CD40‐CD40 Ligand (CD40L) pathway is implicated in autoimmune responses, with elevated levels of soluble CD40L (sCD40L) observed in SLE patients. This study investigates sCD40L as a biomarker for disease activity and its utility in stratifying patients for CD40L‐targeted therapies. Plasma levels of sCD40L were quantified in SLE patients ( n = 169) and healthy controls ( n = 100). Correlations between sCD40L levels and disease activity measures were analysed using Spearman's correlation and logistic regression. K‐means clustering grouped patients based on sCD40L concentrations, and principal component analysis (PCA) was performed to assess relationships among disease activity variables. SLE patients exhibited significantly higher sCD40L levels (median 2.2 ng/mL) than healthy controls (median 0.81 ng/mL; p = 0.0079). Elevated sCD40L levels correlated weakly with higher SLE Disease Activity Index (SLEDAI) scores ( p = 0.0418), positive Anti‐Nuclear Antibody status ( p = 0.0133), increased IgG levels ( p = 0.0148) and decreased lymphocyte counts ( p = 0.0327). Clustering analysis and PCA revealed that patients with higher sCD40L levels tended to have increased disease activity, elevated anti‐dsDNA antibody concentrations, and higher C‐reactive protein (CRP) levels. Elevated sCD40L levels in SLE patients correlate with disease activity markers, suggesting its potential as a biomarker for monitoring disease progression and severity. Additionally, sCD40L may aid in stratifying patients who could benefit from CD40L‐targeted therapies within a treat‐to‐target framework. Further longitudinal studies with larger cohorts are warranted to validate and explore the role of sCD40L in personalised SLE treatment strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lupus Erythematosus, SystemicCD40 LigandHumansMaleFemaleAdultMiddle AgedCross-Sectional StudiesBiomarkersSeverity of Illness IndexAntibodies, AntinuclearCD40 AntigensYoung AdultCohort Studies

Stichwörter der Autor:innen

CD40L inhibitorsbiomarkersCD40L

Substanzen

CD40 LigandBiomarkersAntibodies, AntinuclearCD40 Antigens

Autor:innen und Institutionen

  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Department of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Department of Rheumatology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Kathrine Pedersen

Förderung

  • Danmarks Grundforskningsfond

Zitieren

APA

Pedersen, K., Hansen, A. G., Palarasah, Y., Troldborg, A., & Thiel, S. (2025). Treat‐To‐Target: Emergence of Second‐Generation CD 40 L Inhibitors for Treatment of SLE —Identifying Beneficial Patient Candidates for CD 40 L Inhibitors in a Cross‐Sectional SLE Cohort. Scandinavian Journal of Immunology. https://doi.org/10.1111/sji.70050

Vancouver

Pedersen K, Hansen AG, Palarasah Y, Troldborg A, Thiel S. Treat‐To‐Target: Emergence of Second‐Generation CD 40 L Inhibitors for Treatment of SLE —Identifying Beneficial Patient Candidates for CD 40 L Inhibitors in a Cross‐Sectional SLE Cohort. Scandinavian Journal of Immunology. 2025. doi:10.1111/sji.70050

BibTeX
@article{Pedersen2025,
  author = {Pedersen, Kathrine and Hansen, Annette Gudmann and Palarasah, Yaseelan and Troldborg, Anne and Thiel, Steffen},
  title = {Treat‐To‐Target: Emergence of Second‐Generation CD 40 L Inhibitors for Treatment of SLE —Identifying Beneficial Patient Candidates for CD 40 L Inhibitors in a Cross‐Sectional SLE Cohort},
  journal = {Scandinavian Journal of Immunology},
  year = {2025},
  doi = {10.1111/sji.70050}
}
Kostenlos starten →